ARAZASETRON BESYLATE

ARAZASETRON BESYLATE

R-Azasetron besylate, SENS-401

Cas 2025360-91-0

C₁₇H₂₀ClN₃O₃.C₆H₆O₃S, 507.99, UXP39EQ477

2H-1,4-Benzoxazine-8-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, benzenesulfonate (1:1)

N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide; benzenesulfonic acid

X HCL SALT, CAS , 2139305-21-6, Name2H-1,4-Benzoxazine-8-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-chloro-3,…

BASE: 2025360-90-9

.HCL SALT CAS, 2566443-39-6

Name 2H-1,4-Benzoxazine-8-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-chloro-3,…

BASE: 2025360-90-9

Base CHIRAL 2025360-90-9

• N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-2H-1,4-benzoxazine-8-carboxamide

(R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage.

Arazasetron Besylate is the besylate salt form of the R-enantiomer of azasetron, a benzamide derivative and selective serotonin (5-hydroxytryptamine; 5-HT) receptor and calcineurin antagonist, with potential antinauseant and antiemetic, and otoprotective activities. Upon administration, arazasetron selectively binds to and inhibits 5-HT subtype 3 receptors (5-HT3R) located peripherally on vagus nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema, which may result in suppression of nausea and vomiting. R-azasetron also targets and inhibits the activation of calcineurin, thereby preventing inner ear lesions, nerve degeneration, induction of apoptosis and sensory hair loss. This may prevent hearing loss. Calcineurin activation plays a key role in structural degeneration, swelling, synaptic uncoupling and the induction of apoptosis in the inner ear leading to hair cell loss and hearing loss.

SCHEME

PATENTS

WO2017178645

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017178645&_cid=P22-MCX71S-95827-1

PATENTS 

US20190083503 

https://patentscope.wipo.int/search/en/detail.jsf?docId=US239434911&_cid=P22-MCX73M-97768-1

PATENTS

WO2010/133663

CN101786963

CN104557906

WO201717864

WO2021014014

WO2023175078 

WO2023122719

Base WO2017178645

WO2021014014

WO2023175078 

[1]. Petremann M, et al. SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96 hours. Otol Neurotol. 2019 Feb;40(2):254-263.  [Content Brief][2]. Petremann M, et al. Oral Administration of Clinical Stage Drug Candidate SENS-401 Effectively Reduces Cisplatin-induced Hearing Loss in Rats. Otol Neurotol. 2017 Oct;38(9):1355-1361.  [Content Brief]

//////////ARAZASETRON BESYLATE, R-Azasetron besylate, UXP39EQ477, SENS-401, SENS 401